| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 117,641 | 87,880 | ||
| Marketable securities | 258,162 | 205,047 | ||
| Trade accounts receivable, net of allowance for credit losses of 21,528 as of september 30, 2025, and 20,458 as of december 31, 2024 | 71,187 | 77,190 | ||
| Other current assets | 60,384 | 58,610 | ||
| Total current assets | 507,374 | 428,727 | ||
| Marketable securities, long-term | 411,778 | 484,471 | ||
| Intangible assets, net | 135,255 | 131,060 | ||
| Fixed assets, gross | 166,064 | - | ||
| Fixed assets, net | 111,865 | 110,223 | ||
| Goodwill | 25,080 | 22,055 | ||
| Other long-term assets | 23,211 | 23,302 | ||
| Total assets | 1,214,563 | 1,199,838 | ||
| Accounts payable | 18,088 | 18,887 | ||
| Accrued liabilities | 23,010 | 21,699 | ||
| Customer deposit | 28,543 | 27,600 | ||
| Contract liabilities | 2,309 | 2,673 | ||
| Notes payable, current | 476 | 476 | ||
| Total current liabilities | 72,426 | 71,335 | ||
| Deferred tax liabilities | 7,040 | 6,124 | ||
| Unrecognized tax benefits | 6,783 | 4,838 | ||
| Other long-term liabilities | 7,557 | 5,905 | ||
| Total liabilities | 93,806 | 88,202 | ||
| Common stock, 0.0001 par value per share, 50,000 shares authorized, 34,274 shares issued and 30,854 shares outstanding as of september 30, 2025, and 33,614 shares issued and 30,841 shares outstanding as of december 31, 2024 | 3 | 3 | ||
| Additional paid-in capital | 565,690 | 550,599 | ||
| Accumulated other comprehensive income (loss) | 6,823 | 5,998 | ||
| Retained earnings | 553,372 | 559,980 | ||
| Total fulgent stockholders' equity | 1,125,888 | 1,116,580 | ||
| Noncontrolling interest | -5,131 | -4,944 | ||
| Total stockholders equity | 1,120,757 | 1,111,636 | ||
| Total liabilities and stockholders equity | 1,214,563 | 1,199,838 | ||
Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT)